Guideline Conformity to the Stupp Regimen in Patients with Newly Diagnosed Glioblastoma Multiforme in China

Abstract

<b>Aims:</b> To determine how consistently Chinese glioblastoma multiforme (GBM) patients were treated according to the Stupp regimen. <b>Patients and methods:</b> The proportion of treatments conforming to the Stupp regimen and reasons for nonconformity were evaluated in 202 newly diagnosed GBM patients. <b>Results:</b> Only 15.8% of GBM patients received treatments compliant with the Stupp regimen. The main deviations were temozolomide dosages >75 mg/m² (58/120; 48.3%) and treatment durations <42 days (84/120; 70.0%) in the concomitant phase and temozolomide dosages <150 mg/m² (89/101; 88.1%) in the maintenance phase. Median overall survival (27.09 vs 18.21 months) and progression-free survival (14.27 vs 12.10 months) were longer in patients who received Stupp regimen-compliant treatments. <b>Conclusion:</b> Increased conformity to the Stupp regimen is needed for GBM patients in China.